Table 1.
Relationship between CAD and clinical therapy of tumor.
| Tumor or Model Type | Inhibitors | Target | Clinical Traits (+) or Not (−) | References |
|---|---|---|---|---|
| Colorectal cancer | N-phosphonoacetyl-l-aspartic acid leucovorin |
ATCase | − | [135,136,137] |
| Lymphoma Melanoma |
N-(phosphonacetyl)-L-aspartate (PALA) | ATCase | +, terminated, Clinical phase II | [138,139] |
| Myeloid leukemia | ASLAN003 | DHODH | +, processing in clinical phase II | [35] |
| Myeloid malignancies | BAY 2402234 | DHODH | +, terminated, clinical phase II | [140,141] |
| Myeloma cell lines | AICAr | UMPS | − | [142] |
| central nervous system disorder (multiple sclerosis) | Teriflunomide | DHODH | + | [82] |